WY-50295 | CAS#123016-21-7 | inhibitor

MedKoo Cat#: 145977 | Name: WY-50295

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WY-50295 is a selective inhibitor of the enzyme phosphodiesterase 5 (PDE5), which plays a key role in regulating the levels of cyclic GMP in smooth muscle cells. By inhibiting PDE5, WY-50295 increases the levels of cyclic GMP, leading to vasodilation and improved blood flow, particularly in the pulmonary and systemic circulations. The compound has potential applications in treating conditions like pulmonary arterial hypertension and erectile dysfunction, where enhanced blood flow is beneficial. Its mechanism involves the relaxation of smooth muscle tissue through the cyclic GMP pathway, making it a candidate for improving vascular health and addressing related disorders.

Chemical Structure

WY-50295

CAS#123016-21-7

Theoretical Analysis

MedKoo Cat#: 145977

Name: WY-50295

CAS#: 123016-21-7

Chemical Formula: C23H19NO3

Exact Mass: 357.1400

Molecular Weight: 357.41

Elemental Analysis: C, 77.29; H, 5.36; N, 3.92; O, 13.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

WY-50295; WY50295; WY 50295;

IUPAC/Chemical Name

(S)-2-(6-(quinolin-2-ylmethoxy)naphthalen-2-yl)propanoic acid

InChi Key

QWFAMXAVDCZEBZ-HNNXBMFYSA-N

InChi Code

1S/C23H19NO3/c1-15(23(25)26)17-6-7-19-13-21(11-9-18(19)12-17)27-14-20-10-8-16-4-2-3-5-22(16)24-20/h2-13,15H,14H2,1H3,(H,25,26)/t15-/m0/s1

SMILES Code

C[C@H](C(O)=O)C1=CC=C2C=C(OCC3=NC4=CC=CC=C4C=C3)C=CC2=C1

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 357.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Carlson R, Kreft A, Hartman D, Tomchek L, Lock Y, Weichman B, Glaser K. WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41. doi: 10.1054/plef.1998.0005. PMID: 10319915. 2: Boros V, Burghardt JS, Morgan CJ, Olson DM. Leukotrienes are indicated as mediators of hyperoxia-inhibited alveolarization in newborn rats. Am J Physiol. 1997 Mar;272(3 Pt 1):L433-41. doi: 10.1152/ajplung.1997.272.3.L433. PMID: 9124600. 3: Grimes D, Sturm RJ, Marinari LR, Carlson RP, Berkenkopf JW, Musser JH, Kreft AF, Weichman BM. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur J Pharmacol. 1993 May 19;236(2):217-28. doi: 10.1016/0014-2999(93)90592-6. PMID: 8391458. 4: Weichman BM, Berkenkopf JW, Grimes D, Heaslip RJ, Sturm RJ, Chang JY. WY-50,295 tromethamine: a novel inhibitor of leukotriene-mediated reactions. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:477-80. PMID: 1847784. 5: Heaslip RJ, Grimes D, Berkenkopf JW, Ilsemann BA, Sickels BD, Weichman BM. Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues. Eur J Pharmacol. 1993 Apr 6;234(2-3):247-54. doi: 10.1016/0014-2999(93)90960-p. PMID: 8482329. 6: Pan HL, Stahl GL, Longhurst JC. Differential effect of 5- and 15-lipoxygenase products on ischemically sensitive abdominal visceral afferents. Am J Physiol. 1995 Jul;269(1 Pt 2):H96-105. doi: 10.1152/ajpheart.1995.269.1.H96. PMID: 7631880. 7: Marshall LA, Winkler JD, Griswold DE, Bolognese B, Roshak A, Sung CM, Webb EF, Jacobs R. Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation. J Pharmacol Exp Ther. 1994 Feb;268(2):709-17. PMID: 8113982. 8: DeBOER DJ, Moriello KA, Pollet RA. Inability of Short-duration Treatment with a 5-Lipoxy-genase Inhibitor to Reduce Clinical Signs of Canine Atopy. Vet Dermatol. 1994 Mar;5(1):13-16. doi: 10.1111/j.1365-3164.1994.tb00004.x. PMID: 34645039. 9: Burghardt JS, Boros V, Biggs DF, Olson DM. Lipid mediators in oxygen-induced airway remodeling and hyperresponsiveness in newborn rats. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):837-42. doi: 10.1164/ajrccm.154.4.8887572. PMID: 8887572. 10: Weichman BM, Berkenkopf JW, Chang JY, Heaslip RJ, Kreft AF, Lewis AJ, Musser JH, Grimes D. WY-50, 295 tromethamine: an orally active 5-lipoxygenase inhibitor with anti-allergic activity. Agents Actions Suppl. 1991;34:201-9. PMID: 1793064. 11: Hogaboam CM, Donigi-Gale D, Shoupe TS, Bissonnette EY, Befus AD, Wallace JL. Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds. Br J Pharmacol. 1992 Jan;105(1):87-92. doi: 10.1111/j.1476-5381.1992.tb14215.x. PMID: 1596692; PMCID: PMC1908618. 12: Ochalski SJ, Hartman DA, Belfast MT, Walter TL, Glaser KB, Carlson RP. Inhibition of endotoxin-induced hypothermia and serum TNF-alpha levels in CD-1 mice by various pharmacological agents. Agents Actions. 1993;39 Spec No:C52-4. doi: 10.1007/BF01972718. PMID: 8273585. 13: Howell RE, Sickels BD, Woeppel SL, Jenkins LP, Rubin EB, Weichman BM. Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs. J Pharmacol Exp Ther. 1994 Jan;268(1):353-8. PMID: 8301576. 14: Kreft AF, Failli AA, Musser JH, Kubrak DM, Banker AL, Steffan R, Demerson CA, Nelson JA, Shah US, Gray W, et al. Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugs. Drugs Exp Clin Res. 1991;17(8):381-7. PMID: 1822830. 15: Howell RE, Jenkins LP, Hartman DA, Gray WB, Kubrak D, Carlson RP, Kreft AF, Grimes D. Pulmonary pharmacology of WAY-126299A: a dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist. Inflamm Res. 1995 Aug;44 Suppl 2:S170-1. doi: 10.1007/BF01778316. PMID: 8548382. 16: Sullivan TR Jr, Cordero JA Jr, Mercer DW, Ritchie WP Jr, Dempsey DT. Selective lipoxygenase inhibitor reduces bile acid-induced gastric mucosal injury. J Surg Res. 1992 Dec;53(6):568-71. doi: 10.1016/0022-4804(92)90256-y. PMID: 1494289.